Current diagnostic methods of renal allograft rejection are neither sensitive, nor specific. Needle biopsies are invasive and associated with patient morbidity. It is thus desirable to develop noninvasive tests to predict and diagnose rejection.
UCLA researchers have identified a number of proteins present in human plasma associated with transplant rejection. In a study that enrolled over 500 patients, Reed and coworkers utilized the Banff criteria to establish that 22 proteins were significantly associated with acute allograft rejection. Two of these were positively identified as α-1 anti-chymotrypsin and Apo A1. Plasma concentrations of both protein levels were significantly lower at rejection, compared to post-rejection. Current research is focused on determining the identity of the remaining proteins.
|United States Of America||Issued Patent||10,451,636||10/22/2019||2011-896|
Allograt rejection, renal transplantation, biomarker, antichymotrypsin, plasma biomarker, apolipoprotein a1